Format

Send to

Choose Destination
Nat Med. 2017 Jul;23(7):815-817. doi: 10.1038/nm.4356. Epub 2017 Jun 12.

Elimination of large tumors in mice by mRNA-encoded bispecific antibodies.

Author information

1
BioNTech, Mainz, Germany.
2
Cluster of Individualized Immunointervention (CI3), Mainz, Germany.
3
Department of Internal Medicine III, Johannes Gutenberg University, Mainz, Germany.
4
TRON-Translational Oncology at the University Medical Center of the Johannes Gutenberg University, Mainz, Germany.

Abstract

The potential of bispecific T cell-engaging antibodies is hindered by manufacturing challenges and short serum half-life. We circumvented these limitations by treating mice with in vitro-transcribed pharmacologically optimized, nucleoside-modified mRNA encoding the antibody. We achieved sustained endogenous synthesis of the antibody, which eliminated advanced tumors as effectively as the corresponding purified bispecific antibody. Because manufacturing of pharmaceutical mRNA is fast, this approach could accelerate the clinical development of novel bispecific antibodies.

PMID:
28604701
DOI:
10.1038/nm.4356
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center